Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 7, 2026, by Tango Therapeutics, Inc., a Delaware corporation. The report discloses significant leadership changes effective January 8, 2026, and provides unaudited financial data as of December 31, 2025.
Key Financial Metrics
The filing provides limited financial data, focusing primarily on liquidity:
- Cash Position: As of December 31, 2025, the Company held $343 million in cash, cash equivalents, and marketable securities (unaudited).
- Revenue and Profit: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the period.
- Debt: The filing text does not provide specific values for outstanding debt.
Material Changes and Leadership Transition
The primary material event reported is the resignation of the CEO and the appointment of a successor:
- Resignation: Barbara Weber, M.D., resigned as President and Chief Executive Officer effective January 8, 2026. She will transition to the role of Executive Chair and provide advisory services through December 31, 2026.
- Appointment: Malte Peters, M.D., a current Board member, was appointed President and Chief Executive Officer effective January 8, 2026.
- Compensation Changes:
- Dr. Weber (Executive Chair): Annual base salary of $362,000 and a target cash bonus of 60% of base salary.
- Dr. Peters (CEO): Annual base salary of $720,000 and a target cash bonus of 60% of base salary.
- Equity Grants to Dr. Peters: An option to purchase 1,650,000 shares (vesting 25% after one year, remainder over 36 months) and 350,000 Restricted Stock Units (vesting in three equal annual installments).
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statements regarding the Company's anticipated financial results and research and development programs. Key risks identified include:
- Uncertainty regarding the initiation, timing, progress, and cost of research and development programs and clinical trials.
- Potential for cash resources to be utilized more quickly than expected.
- Enrollment and dosing challenges in clinical trials.
Management stated that Dr. Weber's resignation is not the result of any disagreement with the Company's operations, policies, or practices.
Investor Verification Checklist
- Verify the exact vesting schedules and exercise prices for Dr. Peters' equity grants in the attached Exhibits 10.2 and 10.3.
- Review the full "Risk Factors" section in the Company's Annual Report on Form 10-K filed February 27, 2025, for detailed operational risks.
- Confirm the Company's burn rate and runway based on the $343 million cash balance against upcoming clinical trial milestones.
- Monitor the transition plan for the Executive Chair role to ensure continuity in strategic oversight.